Replies to post #169251 on Biotech Values

[pcrutch]

Read the sub note.

"4 patients received incorrect RBV doses (3 received <50% of the prescribed dose:1 given RBV in the RBV-free arm); all achieved HCV-RNA <25 IU/mL at FU12

3 patients discontinued early:1 patient at Day 3 (violated protocol inclusion criterion), and 2 patients at Day 22 and Day 35 (withdrew consent – patients had undetectable HCV RNA at the time of discontinuation)"

Re 5172

Tolerability/AEs seemed to be an issue at the higher doses(400/800mg). They're moving forward with 100mg.

http://www.natap.org/2013/EASL/EASL_27.htm

http://clinicaltrials.gov/ct2/show/NCT01717326?term=mk-5172&rank=10